SM
TCRR

SG3 Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

SG3 Management’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-114,844
Closed -$977K – 1367
2021
Q3 		$977K Buy
+114,844
New +$1.62M 0.03% 468

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SG3 Management's TCRR Position: Q4 2021 in Review

SG3 Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2021, closing a stake of 114,844 shares — an estimated $977K sold.

SG3 Management first reported a position in TCRR in Q3 2021 and held it in 1 quarter. The position peaked at $977K in Q3 2021. 122 funds tracked by Wall St. Rank hold TCRR as of Q4 2021.

  • SG3 Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • SG3 Management sold 114,844 TCR2 Therapeutics Inc. Common Stock shares in Q4 2021, an estimated $977K.
  • SG3 Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • SG3 Management's TCR2 Therapeutics Inc. Common Stock position peaked at $977K in Q3 2021.
  • 122 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.